中国肿瘤外科杂志Issue(6)：359-362,4.DOI:10.3969/j.issn.1674-4136.2014.06.006
癌基因 c-Src 抑制剂对三阴性乳腺癌的疗效评价
Discussion of the therapeutic effects of oncogene c-Src inhibitor on the triple negative breast cancer
摘要
Abstract
Objective To explore adjuvant therapy on triple negative breast cancer (TNBC).Methods Develop triple negative breast cancer cell MDA-MB-231 cells,comparing with estrogen receptor (ER)and pro-gesterone receptor (PR)positive T47D cells,and HER2 positive Sk-Br-3 cells.They were treated with the in-hibitor of oncogene c-Src.MTT assay was used to measure cell growth.MTT and immunoelectrophoresis were performed to detect the growth of cells and the change of its signaling pathways.Results The c-Src inhibitor partially inhibited cell growth in T47D.It significantly abolished cell proliferation in triple negative MDA-MB-231 cells.However,it has no inhibitory effect on Sk-Br-3 cells.It was found that therapeutic effects of the c-Src inhibitor were related with the blocking cell growth signaling pathways in different cell lines.The HER2 in-hibitor significantly blocked S phase of cell cycles and cell growth in Sk-Br-3 cells,without any effect on MDA-MB-231 cells.Conclusions Inhibition of the tyrosine kinase activity of c-Src is an effective therapy to treat tri-ple negative breast cancer cells.关键词
三阴性乳腺癌/c-Src 基因/c-Src 抑制剂/基因治疗Key words
triple negative breast cancer/oncogene c-Src/c-Src inhibitor/gene therapy引用本文复制引用
周士波,姚宇锋..癌基因 c-Src 抑制剂对三阴性乳腺癌的疗效评价[J].中国肿瘤外科杂志,2014,(6):359-362,4.基金项目
江苏省自然科学基金项目 （）
